Visit main University website

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Find MND Biomarker

Welcome to FindMNDBiomarker, an integrative database that consolidates the proteomic findings in brain tissue and biofluids (CSF and blood) from patients with motor neuron disease (also known as amyotrophic lateral sclerosis). FightMNDBiomarker is designed for users to quickly assess whether their proteins of interest have been identified in other cohorts and biosamples from patients with MND/ALS.

Purpose: The goal of this search platform is to facilitate the comparison and discovery of proteins that may serve as promising and reproducible biofluid biomarkers of brain-specific changes in MND/ALS and to identify markers that should be further targeted for analyses and validation.

Using this database: Searches can be performed by entering the protein UniProt IDs, names and sample types into the relevant search term box using free text entry. For example, entering ‘NEFL’ will generate a list of all publications in which NEFL was identified to be significantly dysregulated.

A searchable and filterable table is provided with the following columns:

  • Name: Gene name corresponding to the UniProt ID
  • UniProt ID: UniProt accession number
  • Publication: Study Reference
  • Condition: e.g.ALS – Control, ALS Fast – ALS Slow
  • Sample Type: Sample type used (Abbreviations: SMNs, single motor neurons; AH, anterior horn; PH, posterior horn)
  • Regulation: Direction of change (upregulated or downregulated)
  • Cohorts: Cohort size used for each study
  • Average age at onset ± standard deviation/age range: Average age at onset of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average age at collection ± standard deviation/age range: Average age at collection of ALS cohorts with standard deviation or age range (if provided by publication)
  • Average PMI (range) (hours): Average postmortem interval with range (if provided by tissue studies)

To cite this database: Further details and application of this search tool are described in our manuscript “title” that can be located with this DOI: _____

Contact: For help contact rachel.tan1@sydney.edu.au
Sort by:
Total Records Found: 2896, showing 100 per page
Biomarker NameUniProt IDPublicationConditionSample TypeRegulationCohortsAverage age at onsetAverage age at collectionAverage PMI
ITIH4 Q14624 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ITIH3 Q06033 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
ITIH3 Q06033 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
ITIH3 Q06033 Zubiri et al. 2018 ALS fast – ALS slow (early stage) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
ITIH3 Q06033 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
ITIH2 P19823 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
ITIH1 P19827 Vu et al. 2023 ALS fast – ALS slow CSF Up 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
ITGBL1 O95965 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
ITGB3 P05106 Zubiri et al. 2018 ALS fast – ALS slow (late stage) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
ITGB3 P05106 Zubiri et al. 2018 ALS fast – ALS slow (early stage) Plasma Up 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
ITGB2 P05107 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
ITGB1 P05556 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
ITGAX P20702 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
ITGA6 P23229 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Up 9 ALS, 8 control 57.6 62.8
ITGA5 P08648 Vassileff et al. 2020 ALS – Control Motor Cortex EVs Down 7 ALS, 3 control
ITGA2B P08514 Zubiri et al. 2018 Late ALS – Early ALS (ALS fast cohort) Plasma Down 8 ALS-fast, 6 ALS-slow 61.3 (48-67) (ALS-fast), 58.1 (35-71) (ALS-slow)
ITGA2B P08514 Filareti et al. 2017 Late ALS – Early ALS PBMCs Up 4 Early-ALS, 4 Late-ALS 50 ± 5 (Early-ALS), 80 ± 4 (Late-ALS)
ITGA1 P56199 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
ITAV P06756 Andrés-Benito et al. 2020 ALS – Control CSF Down 15 ALS, 15 control 61 ± 10.8
ITAL P20701 Andrés-Benito et al. 2020 ALS – Control CSF Down 15 ALS, 15 control 61 ± 10.8
ISOC2 Q96AB3 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
ISLR2 Q6UXK2 Berrone et al. 2023 ALS – Control Plasma Down 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
ISLR2 Q6UXK2 Berrone et al. 2023 sALS – Control Plasma Down 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
ISLR2 Q6UXK2 Berrone et al. 2023 fALS – Control Plasma Down 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
ISLR2 Q5T4F7 Vu et al. 2023 ALS fast – ALS slow CSF Down 6 ALS-fast, 5 ALS-slow 54.3 (ALS-fast), 43.4 (ALS-slow) 55.3 (ALS-fast), 52.2 (ALS-slow)
ISLR O14498 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
ISCU Q9H1K1 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IRS2 Q9Y4H2 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IQSEC2 Q5JU85 Seyfried et al. 2018 ALS – Control Prefrontal cortex Up 8 ALS, 8 control 60 63.5 9.1
IQGAP2 Q13576 Oeckl et al. 2020 ALS – Control Spinal cord Up 8 ALS, 7 control 59 (52-61) 36 (24-90)
IQGAP1 P46940 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
IPO5 O00410 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IPO5 O00410 Seyfried et al. 2018 ALS – Control Prefrontal cortex Down 8 ALS, 8 control 60 63.5 9.1
INSR P06213 Berrone et al. 2023 sALS – Control Plasma Down 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
INHBC P55103 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
INHBC P55103 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
INHBB P09529 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
INF2 A0A0A0MQU1 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
INAFM2 P0DMQ5 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
INA Q16352 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
INA Q16352 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IMPAD1 Q9NX62 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IMPAD1 Q9NX62 Collins et al. 2015 ALS – Control CSF Up 90 ALS, 80 control
IMPA1 P29218 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
IMPA1 P29218 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IMPA1 H0YBL1 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IMPA1 P29218 Umoh et al. 2018 ALS – Control Frontal cortex Down 19 ALS, 10 control 55 59 10.6
IMMT Q16891 Guise et al. 2023 ALS – Control Spinal cord (SMNs) Down 3 ALS, 3 control 69.3 9.2
ILF3 Q12906 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IL6ST P40189 Zhou et al. 2023 BO-ALS – Control CSF Up 4 BO-ALS, 5 SO-ALS, 5 control 63.25 ± 8.02 (BO-ALS), 51.2 ± 6.26 (SO-ALS) 64.25 ± 8.02 (BO-ALS), 52 ± 6.44 (SO-ALS)
IL1A P01583 Berrone et al. 2023 ALS – Control Plasma Down 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
IL18BP O95998 Berrone et al. 2023 ALS – Control Plasma Down 16 ALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
IL18BP O95998 Berrone et al. 2023 sALS – Control Plasma Down 8 sALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
IL18BP O95998 Berrone et al. 2023 fALS – Control Plasma Down 8 fALS, 8 control 62 ± 13 (sALS & fALS) 64 ± 11 (sALS & fALS)
IKGC P01834 Katzeff et al. 2020 ALS – Control Serum Up 28 ALS, 22 control 52.7
IGSF8 Q969P0 Iridoy et al. 2019 ALS – Control Spinal cord (AH) Down 9 ALS, 8 control 57.6 62.8
IGSF21 Q96ID5 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGLV8-61 A0A075B6I0 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGLV7-46 A0A075B6I9 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGLV7-43 P04211 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGLV7-43 P04211 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
IGLV7-43 P04211 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
IGLV4-69 A0A075B6H9 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGLV3-25 P01717 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
IGLV3-25 P01717 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGLV3-21 P80748 Xu et al. 2018 ALS – Control Plasma Down 42 ALS, 18 control 61.8 ± 9.6
IGLV3-19 P01714 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGLV3-19 P01714 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGLV3-1 P06889 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
IGLV3-1 P06889 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGLV2-11 P01707 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGLV1-47 A0A075B6I8 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGLV1-44 P01699 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGLV1 P01701 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGLL1 P15814 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
IGLL1 P15814 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGLL1 P15814 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGLC7 A0M8Q6 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
IGLC7 A0M8Q6 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGLC3 P0CG06 Xu et al. 2018 ALS – Control Plasma Up 42 ALS, 18 control 61.8 ± 9.6
IGLC2 A0A075B6K9 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGKV4-1 P01625 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGKV4-1 P83593 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
IGKV3D-15 A0A087WSY6 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGKV3-15 P04207 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGKV2D P01614 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGKV1D-12 P01611 Xu et al. 2018 ALS – Control Plasma Down 42 ALS, 18 control 61.8 ± 9.6
IGKV1-5 P01598 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGKV1-39 P01612 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGKV1-33 P01594 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
IGKV1-33 P01594 Oeckl et al. 2020 sALS – Control CSF Up 12 ALS, 16 control 66 (57-68) 67 (58-74)
IGKV1 P01602 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGKV1 P01603 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGKC P01834 Barschke et al. 2020 C9-ALS – C9-Control CSF Down 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGJ P01591 Oeckl et al. 2020 ALS – Control CSF Up 26 ALS, 16 control
IGJ P01591 Barschke et al. 2020 C9-ALS – C9-Control CSF Up 16 C9-ALS, 11 asymptomatic C9-controls 60 (51-67)
IGJ P01591 Oeckl et al. 2020 gALS – Control CSF Up 14 gALS, 16 control 54 (52-69) 62 (53-75)
IGHV4-39 P01824 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Down 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGHV3-23 P01779 Leoni et al. 2019 BO-ALS – LO-ALS Plasma Up 14 BO-ALS, 16 LO-ALS (45-85) (BO-ALS), (40-76) (LO-ALS)
IGHV3-23 P01765 Bereman et al. 2018 ALS – Control Plasma Up 34 ALS, 30 control